Category IP Policies

EU Unitary Patent And Court Are Here. Or Are They?

As several countries prepare to sign an international agreement establishing an EU unified patent court, debate still rages over whether the concept of the court, and of a single EU patent, is actually feasible. Some say a unified patent in the near term is a “dead letter,” while one patent lawyer believes that while some technical issues remain, the system will spring into life in the not-too-distant future.

EU Digital Agenda 101: From Supporting Research To Meeting Social Challenges

The following is a reprint from the EU research and development network, Cordis, summarising recent activity on the EU Digital Agenda.

The Digital Agenda for Europe and its 101 actions form a vital part of the overall Europe 2020 strategy for securing smart, sustainable and inclusive growth. The actions are organised in seven pillars, or 'containers': digital single market, interoperability and standards, trust and security, fast and ultra-fast internet access, research and innovation, digital literacy, skills and inclusion, and ICT-enabled benefits for EU society. In the previous part of this story we covered the digital single market, interoperability, security, and fast internet access. Next we look at ICT support for research…

President Obama Calls For Dramatic Increase In R&D, Major Trade Deals

In the annual state of the union speech, newly re-elected US President Obama outlined numerous initiatives aimed at strengthening the United States inwardly, but he also kept his eye on international competitiveness. For instance, he called for a massive increase in research and development, as well as a focus on education and skills, manufacturing, science and innovation, and international trade agreements with Asia and Europe.

Letter Shows US Pressure On Global Fund For Compulsory Licensing, Generics

A 2011 letter from the top Republican on the United States Senate Finance Committee condemned efforts by the Global Fund to train public health officials on the use of flexibilities to the patent system contained in international trade rules. The letter, which also attacked the purchase of generic medicines over brand-name drugs, came just months before the US helped remove the head of the Global Fund, ultimately replacing him with an American official.

Year Ahead In IP, Biotech, Biodiversity: A Trio Fuelling Debates, Opportunities In 2013

The coming year promises to be very interesting at the intersection of intellectual property with biotechnology and biodiversity. Patentability of human genes in the United States, of conventionally bred plants in Europe, plant breeders' rights and the management of regulatory authorisations when patents on genetic traits expire, the future of genetically modified organisms in developing countries, and the usual resistance they are meeting from civil society and famers' groups are some of the issues that will continue to feed debates – and potentially create opportunities - in 2013.